Hernández D, Madrigal A

Language: Spanish
References: 14
Page: 547-549
PDF size: 103.92 Kb.

Text Extraction

No abstract.

REFERENCES

1. Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, et al. Umbilical cord blood expansion with nicotinamide provides longterm multilineage engraftment. J Clin Invest. 2014;124(7):3121-3128

2. Horwitz ME, Cilloni D, Valcarcel D, Frassoni F, Boelens JJ, Jagasia M, et al. Nicord single unit expanded umbilical cord blood transplantation (UCBT): final results of a multicenter phase I/II trial. Blood. 2017;130 Suppl 1:847.

3. Wagner JE, Brunstein CG, DeFor TE, Boitano AE, McKenna D, Sumstad D, et al. Phase 2 trials with Mgta-456, single cord blood units (CBU) expanded with an aryl hydrocarbon receptor (AHR) antagonist, demonstrate uniform engraftment and rapid hematopoietic recovery in patients following myeloablative or non-myeloablative conditioning. Blood. 2017;130 Suppl 1 662.

4. Wagner JE, Brunstein CG, Boitano AE, DeFor TE, McKenna D, Sumstad D, et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2016;18(1):144-155.

5. Fares I, Chagaroui J, Gareau Y, Gingras S, Mayotte N, Csaszar E, et al. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 2014;345(6203):1509-1512.

6. Cohen S, Roy J, Lachance S, Marinier A, Roy DC, Delisle JS, et al. Single UM171 expanded cord blood transplant is feasible, safe, and permits transplantation of better HLA matched cords with very low transplant related mortality. Blood. 2017;130 658.

7. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232-236.

8. Delaney C, Milano F, Cicconi L, Othus M, Becker PS, Sandhu V, et al. Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. Lancet Haematol. 2016;3(7):e330-e339.

9. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73-95ra73.

10. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. Sci Transl Med. 2011;3(95):95ra73.

11. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large b-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.

12. Veluchamy JP, Kok N, van der Vliet HJ, Verheul HMW, de Gruijl TD, Spanholtz J, et al. The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments. Front Immunol. 2017;8:631.

13. Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769-1781.

14. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829-848.